Meningococcal

Meningococcal es un fármaco en desarrollo de Sanofi. Tiene 10 ensayos clínicos registrados, 1 en marcha; lo más avanzado, no aplica.

SNY Sanofi

Sus ensayos

Para qué	Fase	Estado
Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea NCT07621653	no aplica	Reclutando pacientes
Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea NCT02864927	Fase 4	Completado
Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam NCT02640404	Fase 2	Completado
Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation NCT02699840	no aplica	Completado
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier NCT02633787	Fase 4	Completado
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea NCT01642589	Fase 3	Completado
Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children NCT01430611	Fase 4	Completado
Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations NCT01359449	Fase 3	Completado
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine NCT01442675	Fase 2	Completado
A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study NCT06165276	Fase 1	Completado

¿Cuándo se esperan resultados? Está en el calendario, para quien tiene cuenta. Crear una cuenta.

Ensayos del registro público de ClinicalTrials.gov; noticias, de los documentos que la empresa presenta ante la SEC. No son recomendaciones de inversión.